#1 Clinical Trials Search in Europe

Lung neoplasm malignant – Trials in Disease

Go back

Ongoing Clinical Trials for Lung Cancer

There are currently 21 ongoing clinical trials investigating new treatments for lung cancer, including advanced therapies targeting specific genetic mutations, immunotherapy combinations, and novel drug compounds. These trials are being conducted across multiple European countries and involve patients at various stages of the disease, from early resectable cancer to advanced metastatic conditions. (Also known as: Lung neoplasm malignant)

Clinical trial locations

Study of PC14586 for Patients with Advanced Solid Tumors with a Specific TP53 Mutation

This trial is investigating PC14586, an oral medication in film-coated tablet form, for patients with solid tumors that have spread locally or to other parts of the body. The main focus is on tumors with a specific genetic change called the TP53 Y220C mutation.

Inclusion criteria: Participants must be at least 18 years old and have adequate organ function, including liver, kidney, and bone marrow health. They need to have an ECOG performance status of 0 or 1, meaning they can perform daily activities with minimal limitations. The tumor must have the TP53 Y220C mutation confirmed through testing. Patients must have received standard treatment that has since progressed, or they must be ineligible for standard treatment. For women of childbearing potential, a negative pregnancy test is required, and effective birth control must be used during the study.

Exclusion criteria: Patients without the TP53 Y220C mutation cannot participate. Those with tumors that are not locally advanced or metastatic are excluded. Individuals outside the specified age range and those belonging to vulnerable populations requiring special protection are also ineligible.

Focus and goal: The trial evaluates how well PC14586 works in treating tumors with this specific mutation. It assesses the medication’s safety, how the body processes it, and its effectiveness in controlling tumor growth. Regular check-ups, imaging tests, and health assessments monitor the treatment’s impact and any side effects.

Investigational drug: PC14586 works by targeting and stabilizing the mutated form of the p53 protein, which plays a role in controlling cell division and preventing tumor development. This investigational anti-cancer agent is administered orally, with dosage and frequency determined by the study team based on individual needs.

Study of Rilvegostomig (AZD2936) for Adults with Advanced or Metastatic Non-Small Cell Lung Cancer

This trial studies Rilvegostomig (AZD2936), a bispecific antibody given through intravenous infusion, for treating advanced or metastatic non-small cell lung cancer. The medication targets two proteins involved in the immune system’s response to cancer: TIGIT and PD-1.

Inclusion criteria: Participants must be 18 years or older with adequate bone marrow, liver, and kidney function. They need unresectable stage III or stage IV NSCLC confirmed by tissue examination. For Parts A and B, the cancer must have progressed during treatment with a checkpoint inhibitor. For Parts C and D, patients must not have received prior immuno-oncology treatment for metastatic disease. A documented PD-L1 expression is required. Participants should have an ECOG performance status of 0 or 1 and a life expectancy of at least 12 weeks.

Exclusion criteria: Patients with different types of cancer, those who have had recent major surgery, active infections requiring treatment, pregnant or breastfeeding women, those with severe allergic reactions to similar medications, and individuals currently participating in another trial are excluded.

Focus and goal: The study aims to determine the safety and effectiveness of AZD2936 in treating advanced NSCLC. By blocking TIGIT and PD-1, the medication enhances the body’s ability to fight cancer cells. The trial monitors how the treatment is processed and its effects on the immune system and cancer progression.

Investigational drug: AZD2936 is a bispecific antibody that blocks proteins helping cancer cells evade the immune system. It’s administered through intravenous infusion, with frequency depending on group assignment within the study.

Study of Sacituzumab Govitecan and Bevacizumab for Treating Brain Metastases in Patients with Non-Small Cell Lung Cancer

This trial tests a combination of Sacituzumab govitecan and Bevacizumab for treating brain metastases in non-small cell lung cancer patients. Both medications are delivered through intravenous infusion.

Inclusion criteria: Participants must be at least 18 years old with good overall health (ECOG performance status of 0 or 1) and a life expectancy of at least 12 weeks. They need metastatic non-squamous NSCLC that has worsened after immunotherapy and/or platinum-doublet chemotherapy. Brain metastases should not be in critical brain areas and must include at least one untreated lesion of 5 mm or larger. The largest brain metastasis should be no more than 2 cm. Patients must be asymptomatic from brain metastases and on stable doses of corticosteroids and anti-seizure medications. Adequate organ function is required.

Exclusion criteria: Patients who haven’t been treated with platinum-doublet chemotherapy and immune checkpoint inhibitors are excluded. Those with active brain metastases that are symptomatic or clearly worsening, individuals outside the specified age range, and vulnerable populations unable to give consent cannot participate.

Focus and goal: The trial evaluates how effective this combination is in treating brain metastases. Sacituzumab govitecan is an antibody-drug conjugate that targets cancer cells, while Bevacizumab prevents the growth of blood vessels supplying tumors. Regular MRI scans every six weeks monitor the response of brain metastases to treatment.

Investigational drugs: Sacituzumab govitecan combines an antibody with a chemotherapy drug, delivering treatment directly to cancer cells. Bevacizumab blocks the VEGF protein, helping slow tumor growth by cutting off blood supply.

Study on Durvalumab and Domvanalimab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

This trial compares the combination of Durvalumab and Domvanalimab (AB154) versus Durvalumab with placebo in patients with locally advanced, unresectable NSCLC who have completed chemoradiation therapy without disease progression.

Inclusion criteria: Participants must be at least 18 years old with confirmed NSCLC and a PD-L1 status of 1% or higher. They must have completed concurrent chemoradiation therapy without progression, receiving at least two cycles of platinum-based chemotherapy and radiation between 54 and 66 Gy. A WHO performance status of 0 or 1 is required, along with adequate organ and bone marrow function. Tumor tissue samples must be provided before chemoradiation.

Exclusion criteria: Patients with different cancer types, metastatic cancer, those who had surgery to remove their cancer, tumors not showing adequate PD-L1 levels, those who haven’t received platinum-based chemoradiation, cancer that worsened after chemotherapy, individuals under 18, and those unable to give informed consent are excluded.

Focus and goal: The study assesses whether adding Domvanalimab to Durvalumab improves progression-free survival compared to Durvalumab alone. Durvalumab helps the immune system fight cancer by blocking the PD-L1 protein, while Domvanalimab targets the TIGIT protein to further enhance immune response.

Investigational drugs: Both medications are administered through intravenous infusion. Durvalumab blocks PD-L1, and Domvanalimab targets TIGIT, both working to boost the immune system’s ability to recognize and attack cancer cells.

Study on High Dose Dexamethasone for Reducing Post-Surgery Pain in Lung Cancer Patients Undergoing Video-Assisted Thoracoscopic Surgery

This trial investigates whether high-dose Dexamethasone can reduce acute pain after Video-Assisted Thoracoscopic Surgery (VATS) for lobectomy or segmentectomy in patients identified as high-pain-responders.

Inclusion criteria: Participants must be over 18 years old, understand Danish, and have a Pain Catastrophizing Scale score of 20 or higher. They must be scheduled for elective VATS lobectomy or segmentectomy.

Exclusion criteria: Patients not diagnosed with lung cancer, not undergoing VATS lobectomy/segmentectomy, not considered high-pain-responders, outside the age range of 18-64 years, or part of vulnerable populations are excluded.

Focus and goal: The study evaluates whether high-dose Dexamethasone (1 mg per kg body weight) is more effective than a lower dose (8 mg total) in reducing post-surgical pain. The medication is given intravenously after anesthesia. Pain levels, especially when coughing, additional pain relief usage, nausea, and hospital stay length are monitored.

Investigational drug: Dexamethasone is a steroid medication that reduces inflammation and pain. It’s administered through IV after anesthesia, with dosage determined by patient weight or set at a standard lower amount.

Study on Niraparib with Immunotherapy for Patients with SLFN11-Positive Extensive-Stage Small Cell Lung Cancer

This trial tests adding Niraparib to anti-PD-L1 antibody maintenance treatment in extensive-disease small cell lung cancer patients with high SLFN11 expression.

Inclusion criteria: Participants must have extensive-disease small cell lung cancer with high SLFN11 expression confirmed by central laboratory. They must have completed 4 cycles of standard first-line chemo-immunotherapy (platinum-etoposide with atezolizumab or durvalumab) without disease progression. Normal blood, kidney, and liver function are required, along with ECOG performance status of 0-2. Patients must be at least 18 years old and provide written consent.

Exclusion criteria: Patients without extensive-disease small cell lung cancer, those lacking high SLFN11 expression, cancer that progressed after first-line treatment, individuals outside the specified age range, and vulnerable populations are excluded.

Focus and goal: The study assesses whether combining Niraparib with anti-PD-L1 antibody maintenance therapy improves progression-free survival at 3 months. Niraparib is taken orally, while the anti-PD-L1 antibody is given through intravenous infusion.

Investigational drugs: Niraparib is a PARP inhibitor that prevents cancer cells from repairing DNA damage. The anti-PD-L1 antibody (atezolizumab or durvalumab) helps the immune system fight cancer by blocking the PD-L1 protein.

Study on Patritumab Deruxtecan and Zirconium (89Zr) Patritumab Deruxtecan for Patients with Advanced EGFR Mutation Positive Lung Cancer

This trial studies Patritumab Deruxtecan with a radioactively labeled version (89Zr-Patritumab Deruxtecan) to determine the optimal imaging dose in advanced EGFR mutation-positive NSCLC.

Inclusion criteria: Participants must provide informed consent and tumor tissue samples. Women of childbearing potential need negative pregnancy tests and must use effective birth control during the study and for 7 months after. Men must use effective birth control for 4 months after treatment and not donate sperm during this time. Patients need confirmed advanced stage EGFR mutation-positive NSCLC that cannot be treated with curative intent. The disease must be measurable by RECIST 1.1 standards, with at least two lesions of 2 cm or larger. Prior treatment with EGFR TKI is required, and those with T790M mutation must have received third-generation EGFR TKI. Participants must be at least 18 years old with ECOG performance status of 0 or 1 and adequate bone marrow and organ function.

Exclusion criteria: Patients without EGFR mutation-positive cancer, those outside the specified age range, vulnerable populations, those unable to undergo required imaging, or with medical conditions interfering with the study are excluded.

Focus and goal: The study determines the best dose of non-radiolabeled Patritumab Deruxtecan for clear imaging results. PET/CT scans at specific intervals visualize how the medication circulates and targets tumors.

Investigational drugs: Patritumab Deruxtecan targets HER3 receptor on cancer cells, delivering a cytotoxic agent directly to tumors. The radiolabeled version allows visualization on PET/CT scans to measure tumor uptake.

Study on Reduced Dose Intensity of Pembrolizumab and Drug Combination for Patients with Advanced or Metastatic Cancer Responding to Standard Immunotherapy

This trial compares standard immunotherapy with reduced-dose immunotherapy in patients with various advanced cancers who have responded to 6 months of standard treatment.

Inclusion criteria: Participants must be 18 or older with locally advanced or metastatic cancer (including various types of lung cancer, kidney cancer, head and neck cancer, bladder cancer, triple-negative breast cancer, and others listed in the trial). They must be in partial or complete response after 6 months of standard immunotherapy and eligible to continue the same treatment. ECOG performance status should be 0 or 1, and patients must have adequate organ and bone marrow function. Those with brain metastases are allowed if stable. Prior treatment with immunotherapy combined with chemotherapy or certain drug combinations is permitted.

Exclusion criteria: Patients without the specified cancer types, those not showing adequate response after 6 months of immunotherapy, individuals with melanoma not showing partial response, and those treated with specific drug combinations without response are excluded.

Focus and goal: The study evaluates whether reduced-dose checkpoint inhibitors (administered every three months) maintain effectiveness in controlling cancer while potentially reducing side effects. The main checkpoint inhibitors studied include Pembrolizumab, Durvalumab, Avelumab, Nivolumab, Dostarlimab, Atezolizumab, and Cemiplimab.

Investigational drugs: Checkpoint inhibitors block proteins that prevent the immune system from attacking cancer cells. They are administered intravenously, either at standard frequency or every three months in the reduced-dose group.

Comparing Lung Perfusion PET/CT-Guided Versus Standard Planning for Stereotactic Body Radiotherapy in Patients with Primary or Secondary Lung Tumors

This trial compares two radiation treatment planning methods: functional lung imaging using blood flow patterns versus traditional anatomical planning for stereotactic body radiotherapy (SBRT).

Inclusion criteria: Participants must be at least 18 years old with primary or secondary lung tumors scheduled for SBRT. They must be able to undergo lung perfusion PET/CT imaging. Both males and females can participate. Participants must not belong to vulnerable population groups.

Exclusion criteria: Those under 18, unable to provide informed consent, pregnant or breastfeeding, with previous chest radiation, active lung infections, multiple tumors unsuitable for SBRT, severe breathing problems preventing stillness during treatment, known allergies to contrast agents, medical conditions preventing PET/CT scanning, participation in interfering trials, mental or physical conditions interfering with protocol adherence, and inability to attend one-year follow-up visits are excluded.

Focus and goal: The study determines whether blood flow imaging-guided radiation planning results in fewer breathing problems or lung damage after treatment. Participants receive [68Ga]Ga-MAA solution through intravenous injection to create detailed lung blood flow images using PET/CT scanning.

Treatment approach: This isn’t testing medications but rather comparing two radiotherapy planning approaches using functional imaging versus conventional methods to potentially minimize lung damage while treating tumors effectively.

Study of sacituzumab govitecan and zimberelimab treatment before and after surgery for patients with resectable non-small cell lung cancer

This trial tests combining Sacituzumab govitecan and Zimberelimab before and after surgery for resectable NSCLC at stages II to IIIB.

Inclusion criteria: Participants must be at least 18 years old with confirmed non-small cell lung cancer that can be surgically removed at stages II to IIIB. They must have completed required tests including airway tissue sampling (EBUS), PD-L1 testing, and imaging scans (PET-CT and brain MRI). Adequate blood test results are required showing hemoglobin at least 9 g/dL, white blood cell count at least 1500/mm3, and platelet count at least 100,000/μL. Liver function must show bilirubin not more than 1.5 times normal and liver enzymes not more than 2.5 times normal. Kidney function with creatinine clearance of at least 30 mL/min is required. Good physical performance status (ECOG 0-1) is necessary. Women of childbearing potential must use reliable birth control during the study and for 6 months after, not be breastfeeding, and provide proof if unable to become pregnant.

Exclusion criteria: Prior chemotherapy for lung cancer, active or untreated brain metastases, other cancers within 3 years, severe heart conditions, active infections including hepatitis or HIV, significant liver or kidney problems, autoimmune diseases requiring systemic treatment, pregnancy or breastfeeding, known allergies to study medications, participation in other trials within 30 days, mental conditions interfering with study procedures, and any condition the doctor believes would make participation unsafe are excluded.

Focus and goal: The study evaluates how effectively the combination eliminates cancer cells before surgery (neoadjuvant phase) and prevents recurrence after surgery (adjuvant phase). Both medications are given through intravenous infusion.

Investigational drugs: Sacituzumab govitecan combines an antibody with chemotherapy to target cancer cells expressing Trop-2 protein. Zimberelimab is an immunotherapy that blocks PD-1 protein, helping the immune system attack cancer cells.

Study on Acetazolamide with Radiochemotherapy or Radioimmunotherapy for Patients with Small Cell Lung Cancer

This trial studies Acetazolamide combined with radiochemotherapy or radioimmunotherapy for small cell lung carcinoma, aiming to find the best dose when used with these treatments.

Inclusion criteria: Participants must be at least 18 years old. For extensive disease, they need confirmed diagnosis, eligibility for first-line chemo-immunotherapy, having received 1-4 cycles of platinum-etoposide with immunotherapy, and showing response or stable disease by RECIST 1.1 or PERCIST 1.0 criteria. For localized disease, they need confirmed chest-limited diagnosis without prior treatment and starting radiotherapy with platinum-chemotherapy and etoposide. Performance status of 0-2 is required, along with measurable tumor, effective birth control for those of childbearing age, and social security affiliation (for French patients).

Exclusion criteria: Patients without lung carcinoma, those outside the age range, and vulnerable populations are excluded.

Focus and goal: The study determines the maximum tolerated dose and recommended dose of Acetazolamide when combined with radiochemotherapy (for localized disease) or radioimmunotherapy (for extensive disease). Treatment lasts 6-7 weeks for localized and 10 days for extensive disease.

Investigational drugs: Acetazolamide is taken orally and works by inhibiting carbonic anhydrase enzyme. It’s being tested to see if it can enhance the effects of radiotherapy, platinum-based chemotherapy, etoposide, and immunotherapy drugs (atezolizumab or durvalumab).

Summary

These 21 ongoing clinical trials represent a diverse landscape of lung cancer research across Europe, with notable concentrations in France, Germany, Spain, Italy, and Belgium. The trials cover a wide spectrum of disease stages, from early resectable cancer to advanced metastatic disease, and include both non-small cell lung cancer and small cell lung cancer.

Several key themes emerge from this collection of trials. A significant number focus on immunotherapy approaches, either as monotherapy or in combination with other agents. Checkpoint inhibitors such as atezolizumab, durvalumab, and pembrolizumab appear frequently, often combined with novel agents or chemotherapy. Targeted therapies for specific genetic mutations (EGFR, RET fusion, MET alterations, TP53 mutations) are also well represented, reflecting the growing importance of personalized medicine in lung cancer treatment.

The geographic distribution shows that France and Germany are leading in the number of available trials, each hosting 10 or more studies. Spain, Italy, and Belgium also serve as major research hubs with participation in multiple trials. This concentration in Western Europe may reflect both research infrastructure and regulatory frameworks that support clinical trial conduct.

Several innovative approaches are being tested, including combinations of antibody-drug conjugates (such as sacituzumab govitecan and patritumab deruxtecan), bispecific antibodies, personalized cell therapies, and digital health monitoring solutions. Some trials are investigating treatment de-escalation strategies, such as reduced-dose immunotherapy for responding patients, which could improve quality of life while maintaining effectiveness.

The trials also address specific clinical challenges, such as brain metastases treatment, pain management after surgery, and optimal treatment sequencing. Some studies focus on biomarker-driven patient selection, using genetic testing to identify patients most likely to benefit from specific therapies.

For patients considering trial participation, the variety of options across different disease stages and treatment lines provides opportunities regardless of where they are in their cancer journey. However, participation requires meeting specific eligibility criteria, and interested patients should discuss options with their oncologists to determine the most appropriate trial for their individual situation.

Ongoing Clinical Trials on Lung neoplasm malignant

  • Study of Sacituzumab Govitecan and Bevacizumab for Treating Brain Metastases in Patients with Non-Small Cell Lung Cancer

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Safety of Lanreotide and Metformin for Patients with Advanced Gastrointestinal or Lung Carcinoids

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study of osimertinib and febuxostat to improve drug delivery in patients with EGFR-mutated non-small cell lung cancer without brain metastases

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Evaluation of Lung Function Using Xenon Gas with CT Imaging in Lung and Breast Cancer Patients Receiving Radiotherapy

    Not yet recruiting

    4 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Evaluation of Pembrolizumab, Patritumab Deruxtecan, and Drug Combinations in Stage IV Non-Small Cell Lung Cancer: A Phase 2 Umbrella Study

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Greece Hungary Italy Poland Spain

  • Study of Rilvegostomig (AZD2936) for Adults with Advanced or Metastatic Non-Small Cell Lung Cancer

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Denmark France The Netherlands Spain

More information about
Lung neoplasm malignant:

Connected medications: